Vaccine News and Research

Latest Vaccine News and Research

Vaccine candidate produces immune response to antigen in all strains of influenza A

A universal influenza vaccine targeting a protein common to all strains of influenza A has safely produced an immune response in humans. If proven effective, the vaccine could eliminate the practice of creating a new flu vaccine annually to match predicted strains, with major implications for global health.

8 Jun 2011

International coalition launches common platform to end AIDS epidemic

An international coalition of scientists and activists today launched a common platform for ending the AIDS epidemic. Thirty years into the epidemic, as world leaders come together at the United Nations to recommit to a global AIDS response, the broad-based international coalition issued a statement calling for world leaders to support a rational, evidence-based approach to responding to AIDS.

8 Jun 2011

Simcere announces settlement agreement with former Jiangsu Quanyi shareholders

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that a settlement agreement with certain former shareholders and directors of Jiangsu Quanyi Biological Technology Stock Co., Ltd. has become effective.

7 Jun 2011

MMV honors UT Southwestern with Project of the Year for new anti-malarial drug discovery

The discovery of a potential new anti-malarial drug by a UT Southwestern Medical Center-led research team has been awarded Project of the Year by Medicines for Malaria Venture.

7 Jun 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline.

7 Jun 2011

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

Oxford BioMedicaplc, a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc., a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the Company's proprietary 5T4 tumour antigen.

7 Jun 2011

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2011

Focus on getting more people on antiretroviral therapy as AIDS turns 30

Sunday marked the 30th anniversary of the first published report of the disease that came to be known as AIDS, the Los Angeles Times reports. Though the "promise" of a vaccine "has not materialized," "[s]ome progress has been made on other fronts," the newspaper writes.

7 Jun 2011

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline (GSK). This collaboration is aimed at developing a second-generation vaccine against malaria—a deadly disease that kills close to 800,000 people annually, most of them young children under age five in Africa. MVI drives the development of malaria vaccines by joining its scientific, managerial, and field expertise with companies, universities, and governments to test potential malaria vaccines and invest in those with the most promise.

6 Jun 2011

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

6 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Several drug makers plan to lower prices of vaccines for GAVI purchase

Several pharmaceutical companies have pledged to lower the prices of vaccines against childhood illnesses ahead of the GAVI Alliance conference in London next week, the Guardian reports (Quinn, 6/6).

6 Jun 2011

An anniversary — AIDS turns 30

Three decades after the first cases of AIDS were recorded, more than 60 million people have been infected worldwide. Scientists agree that the epidemic is far from over and, even with major treatment advances and improvement in understanding the illness, hurdles remain in the effort to eradicate the disease.

6 Jun 2011

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech today announced the price of ROTAVAC India’s first indigenously developed Rotavirus Vaccine. The vaccine will be sold to global public markets, Governments worldwide including UN procurement agencies at a price of US $ 1.0. Bharat Biotech hopes its new vaccine will help prevent part of the ~ 500,000 child deaths each year caused due to rotavirus diarrhea and improve access to better, affordable rotavirus vaccines.

6 Jun 2011

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

A new therapeutic vaccine to treat obesity by suppressing the appetite-stimulating hormone ghrelin decreases food intake and increases calorie burning in mice, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

GAVI welcomes lower pentavalent vaccine price

In the lead up to its first pledging conference on June 13, the GAVI Alliance announced today it has achieved commitments from two emerging market vaccine manufacturers to lower prices for the life-saving pentavalent vaccine, which protects against five deadly diseases. Developed country manufacturers have also offered price reductions on rotavirus and human papillomavirus, or HPV, vaccines.

5 Jun 2011

Ross River Fever vaccine trials begin

Australian researchers are working on a new vaccine that could protect against mosquito-borne Ross River Fever. They are conducting the world-first trial of the vaccine with positive results reported so far.

5 Jun 2011

Department of Health urges caregivers, parents to update students' immunizations

Parents and caregivers are urged to use the summer break to make sure all students' immunizations are up to date before new regulations take effect in August, the Department of Health said today.

4 Jun 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

4 Jun 2011

Vaccine News and Research

Latest Vaccine News and Research

Vaccine candidate produces immune response to antigen in all strains of influenza A

International coalition launches common platform to end AIDS epidemic

Simcere announces settlement agreement with former Jiangsu Quanyi shareholders

MMV honors UT Southwestern with Project of the Year for new anti-malarial drug discovery

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

Focus on getting more people on antiretroviral therapy as AIDS turns 30

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Several drug makers plan to lower prices of vaccines for GAVI purchase

An anniversary — AIDS turns 30

Bharat Biotech announces the pricing for ROTAVAC vaccine

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

GAVI welcomes lower pentavalent vaccine price

Ross River Fever vaccine trials begin

Department of Health urges caregivers, parents to update students' immunizations

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Vaccine News and Research

Latest Vaccine News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in